IL-4 bone therapy

Details IL-4 bone therapy IL-4 bone therapy

1995-04-07

1998-02-03

Ziska, Suzanne E.

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

800 2, 4241431, 4241451, 4241521, 4241841, C12N 1500, A61K 3900, A61K 39395

Patent

active

057141460

ABSTRACT:
An in vivo assay for selecting a candidate therapeutic for treating osteoporosis. A candidate reagent is administered to an IL-4 transgenic mammal whose cells contain a recombinant IL-4 coding sequence operably lined to a promoter sequence which is transcriptionally active in bone marrow cells. At the time the candidate reagent is first administered the IL-4 transgenic mammal is either symptomatic of, or asymptomatic of, an osteoporotic phenotype. The candidate reagent is selected as a candidate therapeutic for treating osteoporosis if either amelioration of, or delay in the onset of, the osteoporotic phenotype is observed following administration of the candidate reagent to the IL-4 transgenic mammal.

REFERENCES:
patent: 4736866 (1988-04-01), Leder et al.
patent: 5013824 (1991-05-01), Abraams et al.
patent: 5017691 (1991-05-01), Lee et al.
patent: 5041381 (1991-08-01), Abrams et al.
patent: 5082927 (1992-01-01), Pastan et al.
patent: 5175383 (1992-12-01), Leder et al.
Lehn M, W.Y. Weiser, S. Engelhorn, S. Gillis, and H.G. Remold. IL-4 inhibits H.sub.2 O.sub.2 production and antileishmanial capacity of human cultured monocytes mediated by IFN-.gamma.. J. Immunol 143:3020-3024, 1989.
Standiford T.J., R.M. Strieter, K. Kasahara and S.L. Kunkel. Disparate regulation of interleukin 8 gene expression from blood monocytes, endothelial cells, and fibroblasts by interleukin 4. Biochem. Biophys. Res. Commun. 171:531-536, 1990.
Rennick D., G. Yang, C. Muller-Sieburg, C. Smith, N. Arai, Y. Takabe, and L. Gemmell. Interleukin 4 (B-cell stimulatory factor 1) can enhance or antagonize the factor-dependent growth of hemopoietic progenitor cells. Proc. Nat'l. Acad. Sci. USA 84:6889-6893, 1987.
Lacey D.L., J.M. Erdmann, H. Suzuki, and J. Ohara. MC3T3 osteoblastic cells express receptors for and respond to interleukin-4. J. Bone Mineral Res. 6 (supplement 1):S255, 1991.
Imai Y., T. Tsunenari, M. Fukase, and T. Fujita. Quantitative bone histomorphometry and circulating T lymphocyte subsets in postmenopausal osteoporosis. J. Bone Mineral Res. 5:393-399, 1990.
Rosen C.J., K. Usiskin, M. Owens, C.O. Barlascini, M. Belsky, and R.A. Adler. T lymphocyte surface antigen markers in osteoporosis. J. Bone Mineral Res. 5:851-855, 1990.
Ernst D.N., M.V. Hobbs, B.E. Torbett, A.L. Glasebrook, M.A. Rehse, K. Bottomly, K. Hayakawa, R.R. Hardy and W.O. Weigle. Differences in the expression profiles of CD45RB, Pgp-1, and 3G11 membrane antigens and in the patterns of lymphokine secretion by splenic CD4.sup.+ cells from young and aged mice. J. Immunol 145:1295-1302, 1990.
Lewis D.B., K.S. Prickett, A. Larsen, K. Grabstein, M. Weaver, and C.B. Wilson. Restricted production of interleukin 4 by activated human T cells. Proc. Nat'l. Acad. Sci. USA 85:9743-9747, 1988.
Lewis D.B., C.C. Yu, J. Meyer, B.K. English, S.J. Kahn, and C.B. Wilson. Cellular and molecular mechanisms for reduced interleukin 4 and interferon-.gamma. production by neonatal T cells. J. Clin. Invest. 87:194-202, 1991.
Pacifici R., L. Rifas, S. Teitelbaum, E. Slatopolsky, R. McCracken, M. Bergfeld, W. Lee, L.V. Avioli, W.A. Peck. Spontaneous release of interleukin 1 from human blood monocytes reflects bone formation in idiopathis osteoporosis. Proc. Nat'l Acad. Sci. USA 84:4616-4260, 1987.
Killar, L.M., C.A. Hatfield, S.R. Carding, M. Pan, G.E. Winterrowd and K. Bottomly. In vivo administration of interleukin 1 elicits increased Ia antigen expression on B cells through the induction interleukin 4. Eur. J. Immunol 19:2205-2210, 1989.
Brown, M.A., J.H. Pierce, C.J. Watson, J. Falco, J.N. Ihle, and W.E. Paul. B cell stimulatory factor-1/Interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell 50:809-818, 1987.
Parfitt AM. The cellular basis of bone remodeling: The quantum concept reexamined in light of recent advances in the cell biology of bone. Calcif. Tissue Int. 36:S37-S45,1 984.
Mundy GM. Local factors in bone remodeling. Recent Prog. Hormone Res. 45:507-531, 1989.
Thomson BM, J. Saklatvala, and T.J. Chambers, J. Exp. Med. 164:104-112, 1986.
Thomson BM, G.R. Mundy, and T.J. Chambers, J. Immunol 138:775-779,1987.
McSheehy PMJ, 1,25-Dihdroxyvitamin D.sub.3 stimulates rat osteoblastic cells to release a soluble factor that increases osetoclastic bone resorption. J. Clin. Invest. 80:425-429, 1987.
Lewis DB, C.C. Yu, I.A. Forbush, J. Carpenter, T.A. Sato, A. Grossman, D.H. Liggitt, and R.M. Perlmutter. Interleukin 4 expressed in situ selectively alters thymocyte development. J. Exp. Med. 173:89-100, 1991.
Garvin AM, S. Pawar, J.D. Marth, and R.M. Perlmutter. Structure of the murine lck gene and its rearrangement in a murine lymphoma cell line. Mol. Cell Biol. 8:3058-3064, 1988.
Perlmutter RM, J.D. Marth, S.F. Ziegler, A.M. Garvin, S. Pawar, M.P. Cooke, and K.M. Abraham. Specialized protein tyrosine kinase proto-oncogens in hematopoietic cells. Biochim Biophys. Acta. 948:245-262, 1988.
Perlmutter RM, J.D. Marth, D.B. Lewis, R. Peet, S.F. Ziegler, and C.B. Wilson. Structure and expression of lck transcripts in human lymphoid cells. J. Cell Biochem. 38:117-126, 1988.
Marth JD, R. Peet, E.G. Krebs, and R.M. Perlmutter. A lymphocyte-specific protein-tyrosine kinase gene is rearrange and overexpressed in the murine T cell lymphoma LSTRA. Cell 43:393-404, 1985.
Shioi A, S.L. Teitelbaum, F. P. Ross, H.G. Welgus, H.Suzuki, J. Ohara, and D.L. Lacey. Interleukin 4 inhibits murine osteoclast formation in vitro. J. Cell Biochem. 45:272-277, 1991.
Hart P.H., G.F. Vitti, D.R. Burgess, G.A. Whitty, D.S. Piccoli, and J.A. Hamilton. Potential antiinflammatory effects of interleukin 4: Suppression of human monocyte tumor necrosis factor .alpha., interleukin 1, and prostaglandin E.sub.2. Proc. Natl Acad. Sci. USA 86:3803-3807, 1989.
Standiford T.J., R.M. Strieter, S.W. Chensue, J.Westwick, K. Kasahara, and S.L. Kunkel. IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J. Immunol 145:1435-1439.1990.
Leung, D.Y.M. and R.S. Geha. Clinical and immunologic aspects of the hyperimmunoglobulin E syndrome. Hematol/Oncol Clin. N. Amer. 2:81-100, 1988
Vercelli, D., H.H. Jabara, C.Cunningham-Rundles, J.S. Abrams, D.B. Lewis, J. Meyer, L.C. Schneider, D.Y.M. Leung, and R.S. Geha Regulation of immunoglobulin (Ig)E synthesis in the Hypr-IgE Syndrome. J. Clin. Invest. 85:1666-1671, 1990.
Kalu, D.N., C-C. Liu, R.R. Hardin and B.W. Hollis,The Aged rat model of ovarian hormone deficiency bone loss. Endocrinology 124:7-16, 1989.
Matzsch, T., D. Bergqvist, U. Hedner, B. Nilsson, and P. Osergaard. Heparin-induced osteoporosis in rats. Thrombosis and Haemostasis 56:293-294, 1986.
Glajchen, N., F. Ismail, S. Epstein, P.S. Jowell, and M. Fallon. The effect of chronic caffeine administration on serum markers of bone mineral metabolism and bone histomorphometry int he rat. Calcif. Tissue Int. 43:277-280, 1988.
Tsuboyama, T., M. Matsushita, H. Okumura, T. Yamamuro, K. Hanada and T. Takeda. Modification of strain-specific femoral bone density by bone marrow chimerism in mice: A study on the spontaneously osteoporotic mouse (SAM-P/6). Bone 10:269-277, 1989.
Banchereau, J., T. Defrance, J.P. Galizzi, P. Miossec, and F. Rousset. Human interleukin 4. Bull Cancer (Paris) 78:299-306, 1991.
Lian, J., C. Stewart, E. Puchacz, S. Mackowiak, V. Shalhoub, D. Collart, G. Zambetti, and G. Stein. Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression. Proc. Nat'l Acad. Sci. USA 86:1143-1147, 1989.
Noma, Y., P. Sideras, T. Naito, S. Bergstedt-Lindquist, C. Azuma, E. Severinson, T. Tanabe, T. Kinashi, F. Matsuda, Y. Yaoita, and T. Honjo. Cloning of cDNA encoding the murine IgG1 induction factor by a novel strategy using SP6 promoter. Nature (Lond.) 319:640-646, 1986.
Brinster, R.L., J.M. Allen, R.R. Berhringer, R.E. Gelinas, and R.D. Palmiter. Introns increase transcriptional efficiency in transgenic mice. Proc. Nat'l Acad. Sci. USA 85:836-840, 1988.
Tepper, R.I., D.A. Levinson, B.Z. Stanger, J. Campos-Torres, A.K. Abbas, and P. Leder. IL-4 induces allergic-like inflammatory disease and alters T cell development in transgenic mice. Cell 62:457-467, 1

Affiliated with

Also associated with

Rating

IL-4 bone therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IL-4 bone therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-4 bone therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-659952